✦ LIBER ✦

A Phase 1/2 Clinical Trial of Enzyme Replacement in Fabry Disease: Pharmacokinetic, Substrate Clearance, and Safety Studies

✍ Scribed by Christine M. Eng; Maryam Banikazemi; Ronald E. Gordon; Martin Goldman; Robert Phelps; Leona Kim; Alan Gass; Jonathan Winston; Steven Dikman; John T. Fallon; Scott Brodie; Charles B. Stacy; Davendra Mehta; Rosaleen Parsons; Karen Norton; Michael O’Callaghan; Robert J. Desnick

Book ID: 117853565
Publisher: American Society of Human Genetics
Year: 2001
Tongue: English
Weight: 1000 KB
Volume: 68
Category: Article
ISSN: 0002-9297
DOI: 10.1086/318809

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Enzyme replacement therapy in Japanese F

Enzyme replacement therapy in Japanese Fabry disease patients: The results of a phase 2 bridging study

✍ Y. Eto; T. Ohashi; Y. Utsunomiya; M. Fujiwara; A. Mizuno; K. Inui; N. Sakai; T. 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 92 KB

Safety and pharmacodynamic effects of a

Safety and pharmacodynamic effects of a pharmacological chaperone on α-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies

✍ Dominique P Germain, Roberto Giugliani, Derralynn A Hughes, Atul Mehta, Kathy Ni 📂 Article 📅 2012 🏛 BioMed Central 🌐 English ⚖ 307 KB

A Phase 2 study of migalastat hydrochlor

A Phase 2 study of migalastat hydrochloride in females with Fabry disease: Selection of population, safety and pharmacodynamic effects

✍ Giugliani, R.; Waldek, S.; Germain, D.P.; Nicholls, K.; Bichet, D.G.; Simosky, J 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 268 KB

Pharmacokinetic, pharmacodynamic, and sa

Pharmacokinetic, pharmacodynamic, and safety profiles of PEGylated interferon beta-1a in healthy volunteers: Results from two Phase 1 clinical studies

✍ Gudarz Davar; Sandra Richman; Stacy Hitchman; Gabrielle Glick; Meena Subramanyam 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 108 KB

An open-label, switchover trial to asses

An open-label, switchover trial to assess the safety and efficacy of agalsidase beta in patients with Fabry disease treated with agalsidase alfa enzyme replacement therapy

✍ Richards, Sarah; Laney, Dawn; Pervaiz, Muhammad A.; Shankar, Suma 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 62 KB

Dose ranging of adjuvant and antigen in

Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: Safety and immunogenicity of a phase 1/2 clinical trial

✍ Wendy Keitel; Nicola Groth; Maria Lattanzi; Michaela Praus; Anne Katrin Hilbert; 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 950 KB